AndroGel Testosterone Replacement Therapy
AndroGel is a topical gel medication which is approved to be used as testosterone replacement therapy in people with hypogonadism, who do not make enough testosterone. Men who used AndroGel for “Low-T” may not have been tested and may have been placed at unnecessary risks for serious side effects including:
- heart attack
- blood clots
- pulmonary embolism
Marketing for Low T
AndroGel was one of several popular testosterone replacement medications which were heavily marketed for the non-medical condition “Low-T”. Drug companies including AndroGel’s manufacturer, AbbVie, used print advertising, television commercials and internet marketing to describe symptoms and encourage men to ask their doctors about symptoms of Low-T – which may have been normal symptoms of aging.
Many of these men may have been given prescriptions for AndroGel and other medications without ever having blood tests performed to confirm hypogonadism but may have actually had normal testosterone levels for their age and were placed at a higher risk for life-threatening complications.
AndroGel is a testosterone replacement therapy medication which is available in a topical gel form to be applied daily. It is approved to treat low testosterone levels caused by a medical condition known as hypogonadism. Unfortunately, many men who have taken it were exposed to a higher than normal risk for life-threatening events, without ever having been tested for low hormones.
AndroGel was one of several medications which were marketed to treat symptoms of “Low-T” in television commercials, in print ads and on the internet. Low-T was not a diagnosis but a marketing term, coined to describe symptoms of low testosterone in male patients including lack of energy, loss of sex drive and general fatigue.
Many of the supposed symptoms of Low-T were actually normal signs of aging, not a medical condition and did not warrant medical treatment. Some evidence suggests that the majority of men who used AndroGel and other medications for “Low-T” were never tested for low testosterone levels and may have been given the prescription drug unnecessarily. This may have exposed them to serious risks which were life-threatening with no clear medical reason.
AbbVie and other testosterone product manufacturers have been accused of improper marketing and of hiding or downplaying the risk of AndroGel and other drugs.
Men who used AndroGel or other testosterone replacement products may be subject to a two to three times greater risk for serious side effects which may be life-threatening.
These effects may include:
Any of these events may become fatal and result in death.
In 2014, based on publication of two large studies which showed a higher-than-normal risk of heart attack and cardiovascular events like stroke, the Food and Drug Administration (FDA) issued a safety notification, indicating that they were launching an investigation. In mid-2015, based on results of the investigation, the agency required that manufacturers include additional safety warnings on AndroGel and all testosterone products regarding the increased risks.
This was the second change to labeling about testosterone safety after a separate warning had been added in mid-2014 regarding an increased risk of blood clotting events such as deep vein thrombosis. Both the 2014 and 2015 changes include a higher than normal risk of potentially fatal events.
Men who were prescribed or used AndroGel and who experienced a side effect such as heart attack, stroke or clotting event, or loved ones of those who died after using AndroGel, may be eligible for compensation and should seek legal advice.
AbbVie has been negotiations for an AndroGel lawsuit settlement agreement and though there are no guarantees, an AndroGel lawsuit may provide compensation for medical costs, lost wages, pain and suffering or wrongful death.
Read more about Testosterone lawsuits.
Notwithstanding claims relating to this product, the drug/medical device remains approved by the U.S. FDA.